Kailera Therapeutics is an advanced clinical-stage biotechnology company developing a diversified pipeline of GLP-1 therapies for people living with obesity. The company focuses on advancing product candidates that leverage multiple GLP-1-based mechanisms of action and routes of administration to address unmet needs in obesity management. Its lead product candidate, ribupatide (KAI-9531), is a once-weekly injectable GLP-1/GIP receptor dual agonist currently in global Phase 3 trials. Kailera is also developing a once-daily oral tablet formulation of ribupatide, KAI-7535, an oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. The company's pipeline was in-licensed through a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co., Ltd. Kailera holds exclusive rights to the development and commercialization of its product candidates outside of China, Hong Kong, Macau, and Taiwan, while Hengrui conducts clinical trials in China.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage investors.kailera.com
Sector Healthcare IR page investors.kailera.com
Tags
obesity, glp-1, dual agonist, tri-agonist, oral small molecule, injectable peptide, metabolic disease, ribupatide, KAI-9531, KAI-7535, KAI-4729, Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable —
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 27
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure Q3 2026 Q2 2026 Q1 2026
Assets 1.082B 1.211B 624.756M
Net profit -95.665M -111.307M -78.865M

Figure Q3 2026 Q2 2026 Q1 2026
Share price 11.42 22.03 —
P/OCF -2.77 -9.21 —

Filed figures

Figure Dec 2025
Balance sheet detail
Lease liabilities (USD) 10.8M
Cash and deposits (USD) 160M
Right-of-use assets (USD) 10.5M
Reported May 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA

•Ribupatide injection Phase 2b trial and KaiNETIC global Phase 3 program fully enrolled; data expected mid-2027 and mid-2028, respectively

•Safiglipron (KAI-7535) global Phase 2 trial fully enrolled; data now anticipated mid-2027

•KAI-4729 IND now active with U.S. FDA; on track to initiate Phase 1 single-dose injection site/ethnic bridging trial by the end of 2026

•Cash continues to support execution of multiple clinical milestones with runway into mid-2028

WALTHAM, Mass. – November 4, 2026 – Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial results for the third quarter ended September 30, 2026, and provided a summary of recent business highlights.

Kailera is advancing a diversified GLP-1-based pipeline of clinical-stage therapeutic candidates for the treatment of obesity.

October 1, 2026

PDF Version

  • New Phase 1 data highlight flexibility of injection site for ribupatide injection

  • Four additional oral presentations from Hengrui Pharma add to the clinical evidence behind Kailera's pipeline

WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced Phase 1 data for ribupatide injection, a GLP-1/GIP receptor dual agonist currently advancing through global Phase 3 clinical trials, presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, partner Hengrui Pharma delivered four oral presentations highlighting clinical data from programs now in global development by Kailera, including ribupatide injection, oral small molecule GLP-1 receptor agonist safiglipron, also known as KAI-7535 (HRS-7535), and injectable GLP-1/GIP/glucagon receptor tri-agonist KAI-4729 (HRS-4729).

EASD 2026 Presentations

Ribupatide Phase 1 Injection Site Clinical Trial

Kailera's Phase 1 single-dose, crossover trial investigated the effect of injection site on the relative bioavailability and safety of ribupatide injection administered subcutaneously in adults living with obesity or overweight. The trial enrolled 51 participants and consisted of three treatment periods, each with a different injection site (abdomen, upper arm, thigh) administered according to a randomized sequence (n=17 per sequence). Participants received a single 2 mg dose of ribupatide injection on Day 1 of each 29-day period. Plasma drug exposure following subcutaneous ribupatide injection to the upper arm or thigh was similar to that observed following abdominal injection, supporting these sites as alternative injection locations. Ribupatide injection was generally well tolerated irrespective of injection site, with no new safety signals identified; most treatment-emergent adverse events (TEAEs) were mild and gastrointestinal in nature.

Additional Presentations at EASD 2026

Among four additional presentations on GLP-1 therapeutics from partner Hengrui Pharma, new Phase 1 findings for HRS-4729 (KAI-4729) provided an early look at the clinical profile of the investigational GLP-1/GIP/glucagon receptor tri-agonist in obesity.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS-4729, a novel GLP-1/GIP/glucagon triple-receptor agonist: a randomized, double-blind, placebo-controlled Phase 1 study

The randomized, double-blind, placebo-controlled first-in-human trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS-4729 (KAI-4729) injection in adult participants with a baseline BMI ranging from 19 kg/m2 to 35 kg/m2 in the SAD portion and from 28 kg/m2 to 40 kg/m2 in the MAD portion. Participants received once-weekly doses of 1 mg, 4 mg, 8 mg or 12 mg HRS-4729, 4 mg ribupatide (active control) or placebo for 12 weeks. In the MAD portion of the trial at Week 12, participants receiving multiple doses of 12 mg of HRS-4729 (N=10) achieved a mean weight loss of up to 16.0% from baseline and 67.3% mean reduction in liver fat content. Ribupatide (4 mg) (N=10) demonstrated a mean reduction in body weight of 16.7% and 38.4% mean reduction in liver fat content. HRS-4729 and ribupatide injection demonstrated favorable safety and tolerability data consistent with GLP-1-based treatments. Most treatment-emergent adverse events (TEAEs) were mild to moderate and gastrointestinal-related.

Kailera plans to initiate a Phase 1 clinical trial of KAI-4729 outside of China in 2026, with data expected in 2027.

Other presentations by Hengrui Pharma include:

All presentations will be accessible on the Scientific Publications section of the Kailera website following the congress. Additional information can be found on the EASD website.

References:

About Ribupatide

Ribupatide is a GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide) receptor dual agonist peptide being developed as a once-weekly subcutaneous injection and as a once-daily oral pill for the treatment of obesity and overweight. Once-weekly ribupatide injection has been studied in more than 3,000 clinical trial participants who have been dosed with treatment out to 52 weeks, including in multiple late-stage clinical trials conducted by Hengrui in China. Hengrui submitted an NDA to the National Medical Products Administration (NMPA) in China for long-term weight management in adults. In May 2024, Hengrui granted Kailera exclusive global rights outside Greater China to develop, manufacture and commercialize its portfolio of innovative GLP-1 therapeutics, including ribupatide injection and ribupatide oral. Kailera is currently evaluating ribupatide injection for the treatment of obesity in the KaiNETIC global Phase 3 clinical program. Based on compelling clinical data to date, Hengrui is advancing once-daily ribupatide oral to Phase 3 clinical trials in China, and Kailera plans to initiate Phase 3 global trials in the first half of 2027.

About Kailera Therapeutics

Kailera Therapeutics (Kailera) is a clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. With an obesity-first focus, Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for the greatest weight loss. Ribupatide injection is in global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. Kailera is expanding the ribupatide franchise by developing a once-daily oral formulation with the goal of providing an oral option with the potential for compelling weight loss and highly differentiated tolerability. Additionally, Kailera is advancing the development of safiglipron (also known as KAI-7535), a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera’s vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. Kailera is based in Waltham, MA. For more information, visit www.kailera.com and follow us on LinkedIn and X.

Special Note Regarding Kailera Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the profile of product candidates, the potential of Kailera’s portfolio, the timing, design and outcome of research and development activities, including with respect to the timing of initiation and completion of clinical trials and the design and goals of clinical trials, market opportunities for product candidates, and the competitive landscape, and the availability of publications. Forward-looking statements can be identified by terms such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “suggest,” “plan,” “goal,” “vision,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or similar expressions and the negatives of those terms. Kailera cannot assure you that the forward-looking statements in this press release will prove to be accurate. Information in this press release may also include statements relating to past performance, which should not be regarded as a reliable indicator of future performance. Forward-looking statements are based on current expectations and assumptions together with projections of the future which are inherently uncertain, and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, uncertainties inherent in clinical development, regulatory review, manufacturing, competition, market opportunities, reliance on third parties, estimates of capital requirements, needs for additional financing, and other important factors, including those discussed under the caption “Risk Factors” in Kailera’s filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release, and Kailera undertakes no obligation to update or revise any forward-looking statements. Kailera may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements.

September 30, 2026

PDF Version

  • Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m² or higher

  • Topline data now expected in mid-2028

WALTHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the completion of enrollment in the KaiNETIC global Phase 3 clinical program. The KaiNETIC program, which encompasses three trials – KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3 – is evaluating ribupatide injection (also known as KAI-9531), an investigational once-weekly dual GLP-1/GIP receptor agonist peptide, for the treatment of people living with obesity or overweight.

Topline data from KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3 are now expected in mid-2028.

“Obesity is a complex, chronic disease, and millions of people still struggle to find a treatment that meets their needs,” said Scott Wasserman, M.D., Chief Medical Officer, Kailera. “Completing enrollment across all three KaiNETIC trials is an important milestone that brings us one step closer to delivering ribupatide injection to patients as a potential best-in-class medicine.”

About the KaiNETIC Phase 3 Program

KaiNETIC is a global Phase 3 program consisting of three double-blind, randomized, placebo-controlled Phase 3 clinical trials designed to evaluate the efficacy and safety of ribupatide injection for the treatment of obesity or overweight. The trials evaluate ribupatide doses up to 10 mg administered by weekly subcutaneous injection over a period of 76 weeks, with dose titration for up to 24 weeks and a maintenance dose of at least 52 weeks. Participants were enrolled at more than 200 investigative sites across eleven countries in North America, Europe, the United Kingdom, Oceania, and South America.

KaiNETIC-1 enrolled approximately 2,500 adults with a BMI of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with a comorbidity, excluding type 2 diabetes. The primary endpoint is percentage change in body weight from baseline at Week 76.

KaiNETIC-2 enrolled approximately 1,200 adults with a BMI of 27 kg/m² or greater and type 2 diabetes. The co-primary endpoints of this trial are percentage change in body weight from baseline at Week 76 and change in hemoglobin A1c from baseline at Week 76.

KaiNETIC-3 enrolled approximately 1,200 adults with a BMI of 35 kg/m² or greater and without type 2 diabetes. The co-primary endpoints of this trial are percentage change in body weight from baseline compared to placebo at Week 76 and percentage change in body weight from baseline compared to semaglutide 2.4 mg at Week 76.

In KaiNETIC-1 and KaiNETIC-2, participants were randomized to one of five arms – ribupatide 4 mg, 6 mg, 8 mg or 10 mg, or placebo, and both trials will also evaluate ribupatide in a pre-defined subgroup of participants with a BMI of 35 kg/m² or greater. In KaiNETIC-3, participants were randomized to one of four arms – ribupatide 8 mg or 10 mg, placebo, or open-label semaglutide 2.4 mg.

About Ribupatide

Ribupatide is a GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide) receptor dual agonist peptide being developed as a once-weekly subcutaneous injection and as a once-daily oral pill for the treatment of obesity and overweight. Once-weekly ribupatide injection has been studied in more than 3,000 clinical trial participants who have been dosed with treatment out to 52 weeks, including in multiple late-stage clinical trials conducted by Hengrui in China. Hengrui submitted an NDA to the National Medical Products Administration (NMPA) in China for long-term weight management in adults. In May 2024, Hengrui granted Kailera exclusive global rights outside Greater China to develop, manufacture and commercialize its portfolio of innovative GLP-1 therapeutics, including ribupatide injection and ribupatide oral. Kailera is currently evaluating ribupatide injection for the treatment of obesity in the KaiNETIC global Phase 3 clinical program. Based on compelling clinical data to date, Hengrui is advancing once-daily ribupatide oral to Phase 3 clinical trials in China, and Kailera plans to initiate planned global Phase 3 trials in obesity in the first half of 2027.

About Kailera Therapeutics

Kailera Therapeutics (Kailera) is a clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. With an obesity-first focus, Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for the greatest weight loss. Ribupatide injection is in global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. Kailera is expanding the ribupatide franchise by developing a once-daily oral formulation with the goal of providing an oral option with the potential for compelling weight loss and highly differentiated tolerability. Additionally, Kailera is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera’s vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. Kailera is based in Waltham, MA. For more information, visit www.kailera.com and follow us on LinkedIn and X.

Special Note Regarding Kailera Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the profile of product candidates, the potential of Kailera’s portfolio, the timing, design and outcome of research and development activities, including with respect to the timing of initiation and completion of clinical trials and the design and goals of clinical trials, market opportunities for product candidates, and the competitive landscape. Forward-looking statements can be identified by terms such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," “suggest,” "plan," “goal,” “vision,” "potential," "predict," "project," "should," "target," "will," "would," or similar expressions and the negatives of those terms. Kailera cannot assure you that the forward-looking statements in this press release will prove to be accurate. Information in this press release may also include statements relating to past performance, which should not be regarded as a reliable indicator of future performance. Forward-looking statements are based on current expectations and assumptions together with projections of the future which are inherently uncertain, and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, uncertainties inherent in clinical development, regulatory review, manufacturing, competition, market opportunities, reliance on third parties, estimates of capital requirements, needs for additional financing, and other important factors, including those discussed under the caption “Risk Factors” in Kailera’s filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release, and Kailera undertakes no obligation to update or revise any forward-looking statements. Kailera may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements.

Prompts

Kailera Therapeutics, Inc. (ticker KLRA), listed in United States.

ETFs Holding Kailera Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
OZEM 4.62% 211,629 $ 2.582M Nov 17, 2026
HRTS 0.39% 14,039 $ 216.201K Aug 31, 2026
RESM 0.06% 104 $ 2,291.12 Jun 30, 2026
FBCG 0.01% 44,017 $ 745.648K Jul 31, 2026
MSSM 0.01% 4,713 $ 72.58K Aug 31, 2026
AVUS 0.00% 5,200 $ 65.364K Nov 16, 2026
AVUQ 0.00% 919 $ 11.552K Nov 16, 2026